Weifeng Qin1,2, Zhenglin Du3, Jingfa Xiao3, Huilong Duan2, Qiang Shu1, Haomin Li1. 1. The Children's Hospital, Zhejiang University School of Medicine and National Clinical Research Center for Child Health, Hangzhou 310052, PR China. 2. College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, PR China. 3. Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, PR China.
Abstract
Aim: To evaluate the clinical benefits of implementing pharmacogenomics testing for Chinese pediatric patients. Materials & methods : Based on the drug-gene interactions involved in the Clinical Pharmacogenetics Implementation Consortium guidelines, whole-genome sequencing data from the Chinese Academy of Sciences Precision Medicine Initiative project and the medication data of pediatric patients from a children's hospital, the prevalence of the Chinese population with actionable pharmacogenomic variants was calculated, the prescribing pattern for pediatric patients was analyzed. Results: 37.0% of the drugs involved in the Clinical Pharmacogenetics Implementation Consortium guidelines were used by Chinese pediatric patients, 8.91% inpatients and 0.89% outpatients received at least one pharmacogenomics medication, 1.24% (4803) inpatients and 0.16% (2940) outpatients were estimated to be at high risk of pharmacogenomic-related adverse therapeutic outcomes. Conclusion: Implementing pharmacogenomics testing can improve therapeutic outcomes for many Chinese pediatric patients.
Aim: To evaluate the clinical benefits of implementing pharmacogenomics testing for Chinese pediatric patients. Materials & methods : Based on the drug-gene interactions involved in the Clinical Pharmacogenetics Implementation Consortium guidelines, whole-genome sequencing data from the Chinese Academy of Sciences Precision Medicine Initiative project and the medication data of pediatric patients from a children's hospital, the prevalence of the Chinese population with actionable pharmacogenomic variants was calculated, the prescribing pattern for pediatric patients was analyzed. Results: 37.0% of the drugs involved in the Clinical Pharmacogenetics Implementation Consortium guidelines were used by Chinese pediatric patients, 8.91% inpatients and 0.89% outpatients received at least one pharmacogenomics medication, 1.24% (4803) inpatients and 0.16% (2940) outpatients were estimated to be at high risk of pharmacogenomic-related adverse therapeutic outcomes. Conclusion: Implementing pharmacogenomics testing can improve therapeutic outcomes for many Chinese pediatric patients.
Entities:
Keywords:
EHR; adverse drug reactions; pediatric; pharmacogenomics clinical implementation
Authors: Mullin Ho Chung Yu; Marcus Chun Yin Chan; Claudia Ching Yan Chung; Andrew Wang Tat Li; Chara Yin Wa Yip; Christopher Chun Yu Mak; Jeffrey Fong Ting Chau; Mianne Lee; Jasmine Lee Fong Fung; Mandy Ho Yin Tsang; Joshua Chun Ki Chan; Wilfred Hing Sang Wong; Jing Yang; William Chun Ming Chui; Patrick Ho Yu Chung; Wanling Yang; So Lun Lee; Godfrey Chi Fung Chan; Paul Kwong Hang Tam; Yu Lung Lau; Clara Sze Man Tang; Kit San Yeung; Brian Hon Yin Chung Journal: PLoS Genet Date: 2021-02-18 Impact factor: 5.917
Authors: Timothy A Roberts; Jennifer A Wagner; Tracy Sandritter; Benjamin T Black; Andrea Gaedigk; Stephani L Stancil Journal: Clin Transl Sci Date: 2020-10-15 Impact factor: 4.689